COGT — Cogent Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Cogent Biosciences Q1 EPS USD -0.62
Cogent Biosciences Inc expected to post a loss of 52 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Braze, Gulfport Energy, Maplebear
U.S. RESEARCH ROUNDUP-Agiliti, Domino's Pizza, Krystal Biotech
Brief: Cogent Bio Announces Oversubscribed $225 Million Private Placement
Brief: Cogent Biosciences Announces Planned 2024 Milestones For Bezuclastinib And Emerging Portfolio Of Selective And Potent Targeted Therapeutics
U.S. RESEARCH ROUNDUP-Adobe, Oracle, Visa
Brief: Cogent Biosciences Announces Positive Initial Data From Phase 2 Summit Trial Evaluating Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)
U.S. RESEARCH ROUNDUP- Atlassian Corp, Broadcom, Cerevel Therapeutics Holdings
Brief: Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline On Molecular Targets And Cancer Therapeutics
Cogent Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cogent Biosciences Reports Recent Business Highlights And Second Quarter 2023 Financial Results
Cogent Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Cogent Biosciences Says Pricing Of 12.5 Million Shares Of Its Common Stock Offered At A Public Offering Price Of $12.00 Per Share
Brief: Cogent Biosciences Announces Proposed Public Offering Of Common Stock
Brief: Cogent Biosciences Announces Proposed Public Offering Of Common Stock
Brief: Cogent Biosciences Announces Positive Lead-In Data From Ongoing Phase 3 Peak Trial Evaluating Bezuclastinib In Combination With Sunitinib
Cogent Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cogent Biosciences Reports Recent Business Highlights And Q1 2023 Financial Results